John B. Buse

114.1k total citations · 44 hit papers
609 papers, 78.8k citations indexed

About

John B. Buse is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, John B. Buse has authored 609 papers receiving a total of 78.8k indexed citations (citations by other indexed papers that have themselves been cited), including 391 papers in Endocrinology, Diabetes and Metabolism, 250 papers in Molecular Biology and 153 papers in Surgery. Recurrent topics in John B. Buse's work include Diabetes Treatment and Management (304 papers), Diabetes Management and Research (225 papers) and Metabolism, Diabetes, and Cancer (145 papers). John B. Buse is often cited by papers focused on Diabetes Treatment and Management (304 papers), Diabetes Management and Research (225 papers) and Metabolism, Diabetes, and Cancer (145 papers). John B. Buse collaborates with scholars based in United States, United Kingdom and Germany. John B. Buse's co-authors include Ele Ferrannini, Απόστολος Τσάπας, Bernard Zinman, Richard M. Bergenstal, Anne L. Peters, Michael A. Nauck, Rury R. Holman, David R. Matthews, David M. Nathan and Mayer B. Davidson and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

John B. Buse

588 papers receiving 75.6k citations

Hit Papers

Effects of Intensive Glucose Lowering in Ty... 1990 2026 2002 2014 2008 2016 2012 2008 2018 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of Intensive Glucose Lowering in Type 2 Diabetes
    2008 5.5k citations John B. Buse et al. New England Journal of Medicine profile →
  2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    2016 4.9k citations Steven P. Marso, Neil R Poulter et al. New England Journal of Medicine profile →
  3. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2012 3.2k citations Richard M. Bergenstal, John B. Buse et al. Diabetologia profile →
  4. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    2008 3.0k citations David M. Nathan, John B. Buse et al. Diabetes Care profile →
  5. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 2.6k citations Melanie J. Davies, David A. D’Alessio et al. Diabetes Care profile →
  6. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
    2012 2.6k citations Richard M. Bergenstal, John B. Buse et al. Diabetes Care profile →
  7. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
    2014 2.4k citations Richard M. Bergenstal, John B. Buse et al. Diabetes Care profile →
  8. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
    2015 1.9k citations Jennifer B. Green, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  9. The Metabolic Syndrome: Time for a Critical Appraisal
    2005 1.8k citations John B. Buse, Ele Ferrannini et al. Diabetes Care profile →
  10. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    2017 1.5k citations Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine profile →
  11. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    2009 1.2k citations John B. Buse, Lawrence Blonde et al. profile →
  12. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2018 1.1k citations Melanie J. Davies, David A. D’Alessio et al. Diabetologia profile →
  13. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
    2004 1.1k citations John B. Buse et al. Diabetes Care profile →
  14. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 947 citations Melanie J. Davies, Chantal Mathieu et al. Diabetes Care profile →
  15. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    2006 918 citations David M. Nathan, John B. Buse et al. Diabetes Care profile →
  16. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    2008 862 citations John B. Buse et al. profile →
  17. Liraglutide and Renal Outcomes in Type 2 Diabetes
    2017 859 citations Steven P. Marso, Neil R Poulter et al. New England Journal of Medicine profile →
  18. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 834 citations John B. Buse, Deborah J. Wexler et al. Diabetes Care profile →
  19. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
    2006 788 citations John B. Buse et al. Diabetes Care profile →
  20. How Do We Define Cure of Diabetes?
    2009 753 citations John B. Buse et al. Diabetes Care profile →
  21. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
    2010 719 citations John B. Buse et al. profile →
  22. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
    2009 707 citations Bernard Zinman, John B. Buse et al. Diabetes Care profile →
  23. Molecular Biology of Mammalian Glucose Transporters
    1990 699 citations John B. Buse et al. Diabetes Care profile →
  24. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery
    2015 688 citations Jicheng Yu, John B. Buse et al. Proceedings of the National Academy of Sciences profile →
  25. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379
    2013 661 citations John B. Buse, Απόστολος Τσάπας et al. Diabetes Care profile →
  26. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
    2010 651 citations Richard M. Bergenstal, John B. Buse et al. New England Journal of Medicine profile →
  27. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
    2008 637 citations Richard M. Bergenstal, John B. Buse et al. Diabetes Care profile →
  28. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
    2005 626 citations John B. Buse et al. Diabetes Care profile →
  29. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
    2007 597 citations John B. Buse et al. profile →
  30. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
    2015 582 citations John B. Buse, Irl B. Hirsch et al. Diabetes Care profile →
  31. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
    2008 543 citations David M. Nathan, John B. Buse et al. Diabetologia profile →
  32. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2022 532 citations Melanie J. Davies, Chantal Mathieu et al. Diabetologia profile →
  33. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
    2015 528 citations Richard M. Bergenstal, John B. Buse et al. Diabetologia profile →
  34. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs
    2020 491 citations Jicheng Yu, Jinqiang Wang et al. Nature Biomedical Engineering profile →
  35. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
    2012 460 citations John B. Buse, Guntram Schernthaner et al. profile →
  36. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
    2017 413 citations M. Angelyn Bethel, Rishi Patel et al. profile →
  37. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
    2017 409 citations Steven P. Marso, Darren K. McGuire et al. New England Journal of Medicine profile →
  38. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    2019 352 citations John B. Buse, Deborah J. Wexler et al. Diabetologia profile →
  39. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
    2017 305 citations Phillip Banks, John B. Buse et al. New England Journal of Medicine profile →
  40. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    2017 275 citations Rury R. Holman, Bernard Zinman et al. Diabetes Care profile →
  41. COVID-19, Hyperglycemia, and New-Onset Diabetes
    2021 184 citations Chantal Mathieu, John B. Buse et al. Diabetes Care profile →
  42. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    2021 161 citations John B. Buse, Peter Rossing et al. Circulation profile →
  43. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
    2023 120 citations John B. Buse, Darren K. McGuire et al. profile →
  44. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    2025 89 citations Darren K. McGuire, Neil R Poulter et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John B. Buse United States 116 56.3k 26.5k 20.5k 8.8k 7.8k 609 78.8k
Bernard Zinman Canada 106 44.5k 0.8× 18.6k 0.7× 18.0k 0.9× 7.3k 0.8× 5.8k 0.7× 652 63.6k
David R. Matthews United Kingdom 81 44.0k 0.8× 18.3k 0.7× 16.3k 0.8× 13.9k 1.6× 4.8k 0.6× 272 75.4k
Ele Ferrannini Italy 107 29.1k 0.5× 15.2k 0.6× 13.3k 0.7× 11.9k 1.3× 3.2k 0.4× 535 51.5k
Markku Laakso Finland 117 23.4k 0.4× 16.3k 0.6× 11.7k 0.6× 13.5k 1.5× 2.9k 0.4× 673 58.2k
Melanie J. Davies United Kingdom 105 32.1k 0.6× 10.9k 0.4× 10.0k 0.5× 12.5k 1.4× 6.6k 0.9× 1.0k 57.9k
Steven E. Kahn United States 105 21.1k 0.4× 12.7k 0.5× 12.9k 0.6× 13.3k 1.5× 3.1k 0.4× 471 46.7k
Rury R. Holman United Kingdom 76 29.6k 0.5× 10.7k 0.4× 9.2k 0.4× 3.9k 0.4× 3.0k 0.4× 350 40.3k
Steven M. Haffner United States 125 33.2k 0.6× 11.2k 0.4× 11.1k 0.5× 11.4k 1.3× 3.5k 0.5× 518 62.2k
Marja‐Riitta Taskinen Finland 100 24.4k 0.4× 8.8k 0.3× 16.8k 0.8× 6.6k 0.7× 2.3k 0.3× 571 46.0k
Hertzel C. Gerstein Canada 94 26.6k 0.5× 8.8k 0.3× 8.1k 0.4× 7.6k 0.9× 3.3k 0.4× 505 51.2k

Countries citing papers authored by John B. Buse

Since Specialization
Citations

This map shows the geographic impact of John B. Buse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John B. Buse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John B. Buse more than expected).

Fields of papers citing papers by John B. Buse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John B. Buse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John B. Buse. The network helps show where John B. Buse may publish in the future.

Co-authorship network of co-authors of John B. Buse

This figure shows the co-authorship network connecting the top 25 collaborators of John B. Buse. A scholar is included among the top collaborators of John B. Buse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John B. Buse. John B. Buse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiang, Hou-Hsien, Dori Khakpour, Irl B. Hirsch, et al.. (2025). Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit. Diabetes Technology & Therapeutics. 27(9). 747–752. 1 indexed citations
2.
Pasquel, Francisco J., Hou-Hsien Chiang, Dori Khakpour, et al.. (2025). Accuracy of Dexcom G6 Pro Continuous Glucose Monitor in the Intensive Care Setting: TIGHT ICU G6 Study. Diabetes Technology & Therapeutics. 28(1). 10–17.
3.
Barlowe, Trevor, Chelsea Anderson, Robert S. Sandler, et al.. (2024). Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes. Clinical Gastroenterology and Hepatology. 23(5). 739–747. 27 indexed citations
4.
Liu, Wei, Yanfang Wang, Anna R. Kahkoska, et al.. (2023). Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex. Nature Biomedical Engineering. 8(10). 1214–1225. 20 indexed citations
5.
Regan, Jessica A., Robert J. Mentz, Jennifer B. Green, et al.. (2023). Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 8(17). 9 indexed citations
6.
Bethel, M. Angelyn, Susanna R. Stevens, John B. Buse, et al.. (2020). Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation. 141(17). 1360–1370. 10 indexed citations
7.
Danne, Thomas, Vijay N. Joish, Phillip Banks, et al.. (2020). Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone. Diabetes Technology & Therapeutics. 23(1). 70–77. 7 indexed citations
8.
Wang, Zejun, Jinqiang Wang, Hongjun Li, et al.. (2020). Dual self-regulated delivery of insulin and glucagon by a hybrid patch. Proceedings of the National Academy of Sciences. 117(47). 29512–29517. 95 indexed citations
9.
Yang, Jeff Y., Tiansheng Wang, Virginia Pate, John B. Buse, & Til Stürmer‎. (2020). Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene. BMJ Open Diabetes Research & Care. 8(1). e000985–e000985. 23 indexed citations
10.
Kahkoska, Anna R., Xiaotong Jiang, Shivani Agarwal, et al.. (2020). Characterizing the weight-glycemia phenotypes of type 1 diabetes in youth and young adulthood. BMJ Open Diabetes Research & Care. 8(1). e000886–e000886. 8 indexed citations
11.
Buse, John B., Deborah J. Wexler, Απόστολος Τσάπας, et al.. (2019). 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 63(2). 221–228. 352 indexed citations breakdown →
12.
Holman, Rury R., M. Angelyn Bethel, Robert J. Mentz, et al.. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 377(13). 1228–1239. 1503 indexed citations breakdown →
13.
Roep, Bart O., Nanette Solvason, Peter A. Gottlieb, et al.. (2013). Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8 + T Cells in Type 1 Diabetes. Science Translational Medicine. 5(191). 191ra82–191ra82. 127 indexed citations
14.
Buse, John B., Yogish C. Kudva, Tadej Battelino, et al.. (2012). Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study. Diabetes Technology & Therapeutics. 14(7). 644–647. 29 indexed citations
15.
Buse, John B., George Dailey, Richard M. Bergenstal, et al.. (2011). Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience. Diabetes Technology & Therapeutics. 13(6). 601–606. 12 indexed citations
16.
Zinman, Bernard, J. E. Gerich, John B. Buse, et al.. (2010). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)). Diabetes Care. 33(3). 240 indexed citations
17.
Schneider, Alexandra, Lucas Neas, M Herbst, et al.. (2010). Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Particle and Fibre Toxicology. 7(1). 14–14. 88 indexed citations
18.
Schneider, Alexandra, Lucas Neas, M Herbst, et al.. (2008). Endothelial Dysfunction: Associations with Exposure to Ambient Fine Particles in Diabetic Individuals. Environmental Health Perspectives. 116(12). 1666–1674. 110 indexed citations
19.
Nathan, David M., John B. Buse, Mayer B. Davidson, et al.. (2007). Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 51(1). 8–11. 81 indexed citations
20.
Chang, Eugene B., et al.. (1991). Cystic fibrosis transmembrane regulator mRNA expression relative to ion-nutrient transport in spontaneously differentiating human intestinal CaCo-2 epithelial cells.. PubMed. 118(4). 377–81. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bernard Zinman Breakdown of academic impact, for papers by David R. Matthews Breakdown of academic impact, for papers by Ele Ferrannini Breakdown of academic impact, for papers by Markku Laakso Breakdown of academic impact, for papers by Melanie J. Davies Breakdown of academic impact, for papers by Steven E. Kahn Breakdown of academic impact, for papers by Rury R. Holman Breakdown of academic impact, for papers by Steven M. Haffner Breakdown of academic impact, for papers by Marja‐Riitta Taskinen Breakdown of academic impact, for papers by Hertzel C. Gerstein
Rankless by CCL
2026